OC-0281 Phase I/II trial of hafnium oxide nanoparticles activated by SBRT in the treatment of liver cancers. (April 2019) - Chajon, E.; Pracht, M.; De Baere, T.; N'Guyen, F.; Bronowicki, J.; Vendrely, V.; Baumann, A.; Croisé-Laurent, V.; Rio, E.; Rolland, Y.; Le Sourd, S.; Gustin, P.; et al.